Therefore, lowering the cytotoxic effects of TNF-toxic and IL-1β in the CNS by ANGPTL2 suppression may serve as an attractive therapeutic option in the acute phase of ischemic stroke. The gene discussed is IL1B; the disease is ischemic stroke.